Middle East Pharmaceutical Industries Future Growth
Future criteria checks 1/6
Middle East Pharmaceutical Industries is forecast to grow revenue at 13.3% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 17.1% |
Revenue growth rate | 13.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 08 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 510 | N/A | N/A | N/A | 1 |
12/31/2025 | 446 | N/A | N/A | N/A | 1 |
12/31/2024 | 385 | N/A | N/A | N/A | 1 |
6/30/2024 | 367 | 79 | 73 | 104 | N/A |
3/31/2024 | 359 | 76 | 71 | 104 | N/A |
12/31/2023 | 338 | 66 | 62 | 93 | N/A |
9/30/2023 | 328 | 63 | 64 | 92 | N/A |
6/30/2023 | 318 | 59 | 66 | 91 | N/A |
3/31/2023 | 291 | 50 | 62 | 84 | N/A |
12/31/2022 | 303 | 59 | 48 | 69 | N/A |
12/31/2021 | 287 | 66 | 16 | 41 | N/A |
12/31/2020 | 302 | 73 | 5 | 44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 4016's forecast earnings growth is above the savings rate (14.5%).
Earnings vs Market: Insufficient data to determine if 4016's earnings are forecast to grow faster than the SA market
High Growth Earnings: Insufficient data to determine if 4016's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 4016's revenue (13.3% per year) is forecast to grow faster than the SA market (1.3% per year).
High Growth Revenue: 4016's revenue (13.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4016's Return on Equity is forecast to be high in 3 years time